PI3K

PI3K
Name	Phosphoinositide 3-kinase
Organism	Eukaryota

PI3K PI3K is a family of intracellular lipid kinases central to cell signaling, growth, survival, and metabolism. Discovered through biochemical work on receptor tyrosine kinases and viral oncogenes, PI3K activity links cell-surface receptors to downstream effectors and is implicated across oncology, immunology, and metabolism. PI3K research intersects with many institutions, investigators, and clinical programs.

Introduction

PI3K was characterized in landmark studies involving Francis Crick, James Watson, Max Perutz, Sydney Brenner-era molecular biology labs and later elaborated by groups at Harvard University, University of Cambridge, Stanford University, Massachusetts Institute of Technology, and University of California, San Francisco. Early mechanistic work connected PI3K to viral oncogenes studied by investigators at Cold Spring Harbor Laboratory and cancer centers such as Memorial Sloan Kettering Cancer Center and Dana-Farber Cancer Institute. Research consortia funded by agencies like the National Institutes of Health and European Research Council accelerated identification of PI3K roles in signaling cascades studied alongside proteins and complexes from The Rockefeller University, Max Planck Society, Karolinska Institutet, Imperial College London, and Johns Hopkins University.

Structure and isoforms

PI3K comprises multiple classes (I, II, III) defined by subunit composition and catalytic specificity, with prominent isoforms discovered in laboratories at Cold Spring Harbor Laboratory, Yale University, University of Oxford, Columbia University, and University of Tokyo. Class I PI3Ks contain p110 catalytic subunits (isoforms p110α, p110β, p110γ, p110δ) and regulatory subunits (p85 variants) characterized by structural biology groups at European Molecular Biology Laboratory, Scripps Research Institute, University of California, Berkeley, Weizmann Institute of Science, and ETH Zurich. High-resolution structures from teams at Stanford University, University of Cambridge, and Max Planck Institute for Biophysical Chemistry resolved domains such as the Ras-binding domain (RBD), C2 domain, helical domain, and kinase domain. Class II and III PI3Ks—studied at University of Toronto, University of Edinburgh, and Seoul National University—display distinct regulatory motifs and accessory proteins uncovered by collaborations with Cold Spring Harbor Laboratory and The Francis Crick Institute.

Signaling mechanisms and regulation

PI3K is activated downstream of receptors including Epidermal growth factor receptor, Platelet-derived growth factor receptor, Insulin receptor, Toll-like receptors, and B cell receptor studied at centers like Mayo Clinic, Cleveland Clinic, St. Jude Children's Research Hospital, and Fred Hutchinson Cancer Center. Activation often requires interaction with small GTPases such as members of the RAS family whose roles were elucidated at European Molecular Biology Laboratory and University of California, San Diego. Regulatory mechanisms involve tyrosine-phosphorylated adaptors characterized by work at Memorial Sloan Kettering Cancer Center and phosphatases such as PTEN and SHIP whose mutations were mapped by teams at Broad Institute, Wellcome Trust Sanger Institute, Cold Spring Harbor Laboratory, and Institute of Cancer Research. Downstream effectors include AKT1, mTOR, PDK1, and transcription factors whose pathways were dissected at University of Pennsylvania, UCSF, Columbia University, and Duke University.

Biological functions and physiological roles

PI3K signaling regulates processes such as cell proliferation investigated in cancer centers at Royal Marsden Hospital and MD Anderson Cancer Center, metabolism explored at Yale School of Medicine and Karolinska Institutet, immune cell function studied at La Jolla Institute for Immunology and Rockefeller University, neuronal plasticity researched at Massachusetts General Hospital and Cold Spring Harbor Laboratory, and angiogenesis analyzed by teams at Johns Hopkins University Hospital and Kings College London. Roles in organismal physiology were evaluated in model systems at The Jackson Laboratory, European Molecular Biology Laboratory, Max Planck Institute for Developmental Biology, and Wistar Institute, with in vivo phenotypes described using mouse lines developed at Wellcome Trust Sanger Institute and zebrafish studies from European Molecular Biology Laboratory and Harvard Medical School.

Role in disease and therapeutic targeting

PI3K dysregulation contributes to cancer, immunodeficiency, metabolic syndrome, neurological disorders, and inflammatory diseases. Oncogenic mutations in p110α and loss-of-function in PTEN were identified by consortia including The Cancer Genome Atlas and teams at Broad Institute, Dana-Farber Cancer Institute, Memorial Sloan Kettering Cancer Center, Institute of Cancer Research, and Cold Spring Harbor Laboratory. Clinical inhibitors (isoform-specific and pan-PI3K) were developed by pharmaceutical groups at Novartis, Gilead Sciences, AstraZeneca, Pfizer, Roche, Sanofi, and Bristol-Myers Squibb and evaluated in trials run by cooperative groups like EORTC, NCI and industry-academic partnerships at MD Anderson Cancer Center and Mayo Clinic. Drug resistance mechanisms and combination strategies were studied at University College London, Vanderbilt University Medical Center, National Cancer Institute, and Sloan Kettering, while adverse event monitoring involved regulatory agencies such as the Food and Drug Administration and European Medicines Agency.

Research methods and experimental tools

Experimental approaches include structural techniques (X-ray crystallography at Diamond Light Source and Argonne National Laboratory, cryo-EM at EMBL and Max Planck Institute), biochemical assays developed at Scripps Research Institute and Protein Data Bank collaborations, genetic models generated at The Jackson Laboratory and Wellcome Trust Sanger Institute, and high-throughput sequencing projects coordinated by Broad Institute, Wellcome Trust Sanger Institute, NIH-funded centers, and European Molecular Biology Laboratory. Chemical biology toolkits—small-molecule inhibitors, activity-based probes, and PROTACs—were advanced by teams at University of Oxford, University of Cambridge, Imperial College London, and pharmaceutical laboratories at Novartis and Pfizer. Clinical biomarker development and imaging studies were performed at Mayo Clinic, Memorial Sloan Kettering Cancer Center, Massachusetts General Hospital, and University of California, San Francisco to translate PI3K biology into diagnostics and therapies.

Category:Signal transduction proteins